Obermatt
See Similar Stocks →

Viking Therapeutics

NAQ:VKTX · US92686J1060
BiotechnologySmall

360° View

no current rank
Price/Sales16
Price/Earnings61
Price/Book100
Dividend Yield—
Revenue Growth—
Profit Growth4
Capital Growth1
TSR 52w14
Leverage24
Liquidity1
Refinancing39
Combined—
Analyst Opinions17
Pro Holdings51
Opinion Changes76
Market Pulse95

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded2012
Employees55
Websitevikingtherapeutics.com
ISINUS92686J1060
Last UpdateApr 2, 2026
Index & Theme
HematologyObesityDiabetesCardiovascularNeurologyEndocrinologyGastroenterologyHepatologySurgeryHealth CareMedicalTherapeutics

Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel, first-in-class, or best-in-class therapies for metabolic and endocrine disorders. VK2735 Development Program In January 2022, the company an…

Similar Stocks

The companies this stock is ranked against.

Compare Viking Therapeutics with its peers
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Design Therapeutics
NSQ:DSGN
71
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Biomea Fusion
NSQ:BMEA
9
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Olema Pharmaceuticals
NSQ:OLMA
28
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Gain Therapeutics
NMQ:GANX
59
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Kymera Therapeutics
NMQ:KYMR
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →